STACEY RYAN: Open Payments
NPI 1427583111 · OGDENSBURG, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$478 in 21 payments from 8 companies in 2025. Trend: 2023 $712 · 2024 $654 · 2025 $478
Food & beverage: $478
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $162 |
| E.R. Squibb & Sons, L.L.C. | 4 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $71 |
| Neurocrine BioSciences, Inc. | 2 | $54 |
| Janssen Pharmaceuticals, Inc | 2 | $52 |
| Alkermes, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $15 |
Products named: REXULTI, COBENFY, CAPLYTA, INGREZZA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, ARISTADA, ABILIFY MAINTENA.
Industry payments across NY — which companies pay providers there.
